Premium
Induction of apoptosis and inhibition of cell proliferation by the lipido‐sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia
Author(s) -
Vacherot Francis,
Azzouz Mohamed,
GilDiezdeMedina Sixtina,
Colombel Marc,
De La Taille Alexandre,
Lefrère Belda MarieAude,
Abbou Claude C.,
Raynaud JeanPierre,
Chopin Dominique K.
Publication year - 2000
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/1097-0045(20001101)45:3<259::aid-pros9>3.0.co;2-g
Subject(s) - apoptosis , hyperplasia , stroma , prostate , cell growth , epithelium , medicine , cell , pathology , staining , programmed cell death , cancer research , biology , immunohistochemistry , cancer , biochemistry , genetics
BACKGROUND To determine the mechanism by which prostate volume increases during the development of BPH and to evaluate the effect of LSESr (Permixon®), a phytotherapeutic agent, we investigated apoptosis and cell proliferation in the stroma and epithelium of normal prostate and of BPH tissues from patients treated with or without LSESr. METHODS MIB‐1 staining and the in situ end‐labeling assay were used to evaluate the proliferative‐apoptotic balance in normal prostates and in BPH tissues. Quantitative assessment was performed using an image analysis system. RESULTS In normal prostates, there was no significant difference between apoptotic and proliferative indices. Cell numbers and proliferative indices were higher in BPH than in normal prostates, while apoptosis values were similar. In the BPH treated group, LSESr significantly inhibited proliferation and induced cell death in both epithelium and stroma. CONCLUSIONS Induction of apoptosis and inhibition of cell proliferation are likely to be the basis for the clinical efficacy of LSESr. Prostate 45:259–266, 2000. © 2000 Wiley‐Liss, Inc.